Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chondrosarcoma (CS) is a common bone sarcoma resistant to conventional therapies.
• Effective treatments for chondrosarcoma are limited due to radio- and chemo-resistance.

Purpose of the Study:

• To evaluate the anti-tumoral effects of GSK-J4, a histone demethylase inhibitor, in chondrosarcoma.
• To investigate the efficacy of GSK-J4 alone and in combination with cisplatin against chondrosarcoma cells.

Main Methods:

• Utilized human chondrosarcoma cell lines treated with GSK-J4 and cisplatin.
• Assessed cell proliferation, cell cycle progression, apoptosis, and senescence.
• Employed flow cytometry with carboxyfluorescein succinimidyl ester and propidium iodide staining.

Main Results:

• GSK-J4 significantly decreased chondrosarcoma cell proliferation.
• GSK-J4 induced apoptosis in specific chondrosarcoma cell lines (CH2879, JJ012) but not others (SW1353).
• Combination therapy with GSK-J4 and cisplatin enhanced proliferation reduction compared to monotherapy but did not increase apoptosis.

Conclusions:

• Histone demethylase inhibitors like GSK-J4 show potential for reducing chondrosarcoma proliferation.
• Combination therapy may offer improved therapeutic strategies for chondrosarcoma by targeting proliferation.
• GSK-J4 demonstrated safety for normal chondrocytes at tested concentrations.